BioCentury | Feb 15, 2016
Company News

Baylor, UCB deal

...UCB and Baylor partnered to discover therapies to treat neurodegenerative diseases. The university uses functional genetics to...
BioCentury | Jan 23, 2014
Cover Story

Regeneron revisits genomics

Regeneron Pharmaceuticals Inc. has opened a new genetics center tasked with analyzing the genomes of at least 100,000 Geisinger Health System patients in the next 5 years. The company hopes the volume of data, diversity...
BioCentury | May 16, 2013
Tools & Techniques

CRISPR model building

Boston researchers have used the CRISPR-Cas9 genome modification platform to simultaneously engineer mutations into multiple genes in mice. 1 The results from the rapid, one-step process provide the best evidence to date for the potential...
BioCentury | Jan 31, 2013
Cover Story

CRISPR genome editing

Five separate research teams have developed a Cas9 endonuclease-based method for sequence-specific genome modification that is guided by DNA-RNA base pairing, and at least two companies are commercializing the findings. 1-6 Although the approach is...
BioCentury | Mar 29, 2012
Targets & Mechanisms

PARP target practice

Swedish researchers have used an in vitro screen to evaluate the target selectivity of a panel of small molecule poly(ADP-ribose) polymerase inhibitors. 1 The findings could eventually lead to next-generation compounds with a better therapeutic...
BioCentury | Nov 21, 2011
Clinical News

FGI-101-1A6: Phase Ia data

...The company is preparing to begin a Phase II trial in an infectious disease population. Functional Genetics Inc....
BioCentury | Feb 3, 2011
Cover Story

Biglycan meets utrophin

...of anatomy at the University of Oxford and honorary director of the Medical Research Council functional genetics...
BioCentury | Feb 25, 2010
Targets & Mechanisms

Pushing the viral envelope

...that drug resistance may be minimal with LJ001," said Michael Kinch, VP of R&D at Functional Genetics Inc....
...are less likely to elicit resistance because they are not under the virus' direct control. Functional Genetics...
...Mentioned Catholic University Leuven , Leuven, Belgium Defense Threat Reduction Agency , Fort Belvoir, Va. Functional Genetics Inc....
BioCentury | Jul 10, 2008
Targets & Mechanisms

Myeloma's IRF4 Addiction

A paper published in Nature suggests that inhibiting interferon regulatory factor 4 could be useful for treating multiple myeloma (MM). Although the study identified the transcription factor as a regulator of several gene pathways central...
BioCentury | May 8, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Psoriasis Corneodesmosin (CDSN) A study in mice suggests that targeting CDSN could help treat psoriasis. CDSN-deficient mice showed aberrant detachment...
Items per page:
1 - 10 of 15
BioCentury | Feb 15, 2016
Company News

Baylor, UCB deal

...UCB and Baylor partnered to discover therapies to treat neurodegenerative diseases. The university uses functional genetics to...
BioCentury | Jan 23, 2014
Cover Story

Regeneron revisits genomics

Regeneron Pharmaceuticals Inc. has opened a new genetics center tasked with analyzing the genomes of at least 100,000 Geisinger Health System patients in the next 5 years. The company hopes the volume of data, diversity...
BioCentury | May 16, 2013
Tools & Techniques

CRISPR model building

Boston researchers have used the CRISPR-Cas9 genome modification platform to simultaneously engineer mutations into multiple genes in mice. 1 The results from the rapid, one-step process provide the best evidence to date for the potential...
BioCentury | Jan 31, 2013
Cover Story

CRISPR genome editing

Five separate research teams have developed a Cas9 endonuclease-based method for sequence-specific genome modification that is guided by DNA-RNA base pairing, and at least two companies are commercializing the findings. 1-6 Although the approach is...
BioCentury | Mar 29, 2012
Targets & Mechanisms

PARP target practice

Swedish researchers have used an in vitro screen to evaluate the target selectivity of a panel of small molecule poly(ADP-ribose) polymerase inhibitors. 1 The findings could eventually lead to next-generation compounds with a better therapeutic...
BioCentury | Nov 21, 2011
Clinical News

FGI-101-1A6: Phase Ia data

...The company is preparing to begin a Phase II trial in an infectious disease population. Functional Genetics Inc....
BioCentury | Feb 3, 2011
Cover Story

Biglycan meets utrophin

...of anatomy at the University of Oxford and honorary director of the Medical Research Council functional genetics...
BioCentury | Feb 25, 2010
Targets & Mechanisms

Pushing the viral envelope

...that drug resistance may be minimal with LJ001," said Michael Kinch, VP of R&D at Functional Genetics Inc....
...are less likely to elicit resistance because they are not under the virus' direct control. Functional Genetics...
...Mentioned Catholic University Leuven , Leuven, Belgium Defense Threat Reduction Agency , Fort Belvoir, Va. Functional Genetics Inc....
BioCentury | Jul 10, 2008
Targets & Mechanisms

Myeloma's IRF4 Addiction

A paper published in Nature suggests that inhibiting interferon regulatory factor 4 could be useful for treating multiple myeloma (MM). Although the study identified the transcription factor as a regulator of several gene pathways central...
BioCentury | May 8, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Psoriasis Corneodesmosin (CDSN) A study in mice suggests that targeting CDSN could help treat psoriasis. CDSN-deficient mice showed aberrant detachment...
Items per page:
1 - 10 of 15